Evercore ISI analyst Gavin Clark-Gartner downgraded Spero Therapeutics (SPRO) to In Line from Outperform with a $5 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRO:
- Spero Therapeutics downgraded to Hold from Buy at TD Cowen
- Spero Therapeutics: Strategic Shift and Earnings Update
- Spero Therapeutics reports Q3 EPS (32c), consensus (36c)
- SPRO Upcoming Earnings Report: What to Expect?
- Spero Therapeutics price target lowered to $5 from $7 at H.C. Wainwright
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
